PGNY · Progyny, Inc.
$31.19
-2.63% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
41.0
Forward P/E
14.1
Dividend yield
—
Beta
1.02
Avg volume
1M
Employees
1K
2D change
—
5D change
2.90%
10D change
-1.06%
30D change
10.80%
60D change
23.59%
MTD change
7.27%
YTD change
23.01%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PGNY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
Barclays
Equal-Weight$34.00
+9.0% vs priceBank of America
Buy$31.00
-0.6% vs priceJP Morgan
Neutral$26.00
-16.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | Barclays | Downgrade | Overweight → Equal-Weight | $27.00 → $34.00 |
| 2026-07-24 | BTIG | Maintains | Buy | $30.00 → $40.00 |
| 2026-07-21 | Canaccord Genuity | Maintains | Buy | $30.00 → $36.00 |
| 2026-07-13 | Keybanc | Maintains | Overweight | $30.00 → $35.00 |
| 2026-06-22 | Truist Securities | Maintains | Buy | $30.00 → $33.00 |
| 2026-06-02 | Bank of America | Maintains | Buy | $29.00 → $31.00 |
| 2026-05-19 | Canaccord Genuity | Upgrade | Hold → Buy | $19.00 → $30.00 |
| 2026-05-18 | Barclays | Maintains | Overweight | $23.00 → $27.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.5% above the 50-day MA ($27.83).
- Price vs 200-day MA: Trading 33.0% above the 200-day MA ($23.13).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.30) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($32.36).
PGNY Price Chart
Loading chart for PGNY…
Fundamentals
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
More in Healthcare Plans
UNH
UnitedHealth Group Incorporated
$379B 28.2% YTD
CVS
CVS Health Corporation
$137B 38.1% YTD
ELV
Elevance Health, Inc.
$82B 9.0% YTD
CI
The Cigna Group
$77B 6.9% YTD
CNC
Centene Corporation
$32B 55.7% YTD
MOH
Molina Healthcare Inc
$10B 14.9% YTD
OSCR
Oscar Health, Inc.
$9B 97.2% YTD
ALHC
Alignment Healthcare, Inc.
$4B -5.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.